WiCell Teams with Agilent Technologies
News Dec 05, 2012
Agilent Technologies Inc. and WiCell have announced that WiCell is now offering comparative genomic hybridization plus single nucleotide polymorphism microarray analysis using the Agilent SurePrint G3 Human Genome CGH+SNP Microarray.
Unlike previous assays that required performing CGH and SNP separately, the CGH+SNP Microarray detects copy number changes by both SNP and CGH, and simultaneously delivers copy-neutral change information such as loss or absence of heterozygosity.
The assay maintains the high-resolution quality achieved with CGH-only microarrays, using probes that have been carefully optimized and validated for maximal sensitivity and specificity.
“WiCell’s considerable experience and know-how in cytogenetic analysis and their large CGH dataset for embryonic and induced pluripotent stem cells, partners well with Agilent’s technology to enable robust detection capabilities vital for research and commercial development,” said Kathleen Shelton, senior director of genomics marketing at Agilent.
Anita Bhattacharyya, Ph.D., senior scientist at University of Wisconsin-Madison’s Waisman Center, understands firsthand the value of WiCell’s CGH+SNP microarray service: “In my Down syndrome research, I needed the ability to rule out loss of heterozygosity in order to publish my research. I was very happy with my interactions with WiCell; their level of expertise and understanding of what I needed was exceptional. Ultimately, through running the SurePrint CGH+SNP microarray, WiCell allowed me to confidently produce the data within a compressed timeline.”
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE